GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Beneish M-Score

APLS (Apellis Pharmaceuticals) Beneish M-Score : 12.51 (As of Dec. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 12.51 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Apellis Pharmaceuticals's Beneish M-Score or its related term are showing as below:

APLS' s Beneish M-Score Range Over the Past 10 Years
Min: -3.35   Med: 2.79   Max: 364.84
Current: 12.51

During the past 11 years, the highest Beneish M-Score of Apellis Pharmaceuticals was 364.84. The lowest was -3.35. And the median was 2.79.


Apellis Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Apellis Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Beneish M-Score Chart

Apellis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -3.35 -1.11 1.51

Apellis Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.42 1.51 2.79 11.12 12.51

Competitive Comparison of Apellis Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Apellis Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apellis Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Beneish M-Score falls into.



Apellis Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Apellis Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5794+0.528 * 0.9805+0.404 * 36.7006+0.892 * 2.621+0.115 * 0.9103
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4485+4.679 * -0.047529-0.327 * 2.0526
=12.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $284.0 Mil.
Revenue was 196.83 + 199.685 + 172.325 + 146.377 = $715.2 Mil.
Gross Profit was 163.273 + 176.585 + 152.116 + 126.465 = $618.4 Mil.
Total Current Assets was $833.9 Mil.
Total Assets was $901.9 Mil.
Property, Plant and Equipment(Net PPE) was $20.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.8 Mil.
Selling, General, & Admin. Expense(SGA) was $521.3 Mil.
Total Current Liabilities was $191.3 Mil.
Long-Term Debt & Capital Lease Obligation was $463.7 Mil.
Net Income was -57.445 + -37.657 + -66.423 + -88.576 = $-250.1 Mil.
Non Operating Income was 0.07 + -1.925 + -0.499 + 0.219 = $-2.1 Mil.
Cash Flow from Operations was 34.096 + -8.339 + -132.983 + -97.875 = $-205.1 Mil.
Total Receivables was $187.0 Mil.
Revenue was 110.399 + 94.969 + 44.846 + 22.663 = $272.9 Mil.
Gross Profit was 87.989 + 86.59 + 37.037 + 19.738 = $231.4 Mil.
Total Current Assets was $796.8 Mil.
Total Assets was $818.2 Mil.
Property, Plant and Equipment(Net PPE) was $20.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.6 Mil.
Selling, General, & Admin. Expense(SGA) was $443.5 Mil.
Total Current Liabilities was $185.6 Mil.
Long-Term Debt & Capital Lease Obligation was $103.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(283.969 / 715.217) / (186.989 / 272.877)
=0.397039 / 0.68525
=0.5794

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(231.354 / 272.877) / (618.439 / 715.217)
=0.847833 / 0.864687
=0.9805

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (833.897 + 20.439) / 901.866) / (1 - (796.767 + 20.274) / 818.216)
=0.052702 / 0.001436
=36.7006

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=715.217 / 272.877
=2.621

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.642 / (1.642 + 20.274)) / (1.833 / (1.833 + 20.439))
=0.074922 / 0.082301
=0.9103

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(521.271 / 715.217) / (443.482 / 272.877)
=0.728829 / 1.625208
=0.4485

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((463.656 + 191.26) / 901.866) / ((103.837 + 185.63) / 818.216)
=0.726179 / 0.353778
=2.0526

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-250.101 - -2.135 - -205.101) / 901.866
=-0.047529

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Apellis Pharmaceuticals has a M-score of 12.51 signals that the company is likely to be a manipulator.


Apellis Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Apellis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Executives
James George Chopas officer: See Remarks 950 WINTER STREET, WALTHAM MA 02451
A. Sinclair Dunlop director C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets officer: Chief Operating Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Timothy Eugene Sullivan officer: Chief Financial Officer 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Mark Jeffrey Delong officer: Senior Vice President 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson officer: Chief Technical Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Cedric Francois director, 10 percent owner, officer: Chief Executive Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Adam J. Townsend officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson officer: General Counsel 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Karen Lewis officer: Chief People Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Jeffrey Eisele officer: See Remarks APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Caroline Baumal officer: Chief Medical Officer C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Lukas Scheibler officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels director 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014